XERIS BIOPHARMA HOLDINGS INC (XERS)
Health Care · Rare disease biopharmaceuticals · NASDAQ
A commercial-stage biopharma company with three FDA-approved therapies for rare endocrine and neurological diseases and a proprietary injectable drug formulation platform for rare diseases.
What XERIS BIOPHARMA HOLDINGS INC does
Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. The company currently commercializes three FDA-approved products: Recorlev (for endogenous hypercortisolemia in Cushing's syndrome), Gvoke (ready-to-use liquid-stable glucagon for severe hypoglycemia), and Keveyis (for Primary Periodic Paralysis). Xeris also leverages its proprietary XeriSol and XeriJect non-aqueous formulation technologies to develop new therapies and pursue partnerships to enhance the drug delivery of other companies' compounds.
Themes: ["Cushing's syndrome / endocrine disorders","Severe hypoglycemia / diabetes complication treatment","Primary Periodic Paralysis / rare neuromuscular disease","Injectable drug formulation / delivery technologies","Orphan / rare disease"]
Fundamentals
- Price$8.62 as of 2026-07-09 close
- Market cap$1.5B as of 2026-07-10
- 1-year return+61.4% as of 2026-07-09 close
- P/E123.13 as of 2026-07-10
- Net margin+3.8% as of 2026-07-10
- Gross margin+85.9% as of 2026-07-10
- ROE+99.7% as of 2026-07-10
- Debt / equity17.00 as of 2026-07-10
- Revenue growth (YoY)+41.5% as of 2026-07-10
- Revenue CAGR (3y)+38.3% SEC XBRL
- Beta0.75 as of 2026-07-10
Key risks (from latest filing)
["Recorlev faces competition from established medications and older generic drugs used off-label for Cushing's syndrome treatment, which could limit market penetration and revenue growth.","Clinical development of XP-8121 depends on successful Phase 3 trial initiation and completion in 2026, with delays or failures potentially impacting the company's pipeline value.","The company carries significant debt ($221.2 million in long-term debt as of March 31, 2026) relative to its modest profitability, creating financial leverage risk and limiting flexibility."]
Competitors & peers
- Corcept Therapeutics (CORT) - competes in Cushing's syndrome treatment
- Novo Nordisk - competes in glucagon for severe hypoglycemia
- Eli Lilly - competes in glucagon products for severe hypoglycemia
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.